Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.57 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20293883 | 1.00 | GRIN2B (0.57) | GRIN2BGRIN2CCTSLMEN1MAPT | |
| SCHEMBL17352433 | 1.00 | GRIN2B (0.57) | GRIN2BGRIN2CCTSLMEN1MAPT | |
| SCHEMBL19627478 | 1.00 | GRIN2B (0.57) | GRIN2BGRIN2CCTSLMEN1MAPT | |
| SCHEMBL27336564 | 0.97 | GRIN2B (0.54) | GRIN2BGRIN2CCTSLMEN1MAPT | |
| SCHEMBL19614446 | 0.89 | GRIN2B (0.41) | GRIN2BGRIN2C | |
| SCHEMBL19614444 | 0.89 | GRIN2B (0.41) | GRIN2BGRIN2C | |
| SCHEMBL19614431 | 0.89 | GRIN2B (0.41) | GRIN2BGRIN2C | |
| SCHEMBL19614432 | 0.89 | GRIN2B (0.41) | GRIN2BGRIN2C | |
| SCHEMBL19614434 | 0.89 | GRIN2B (0.41) | GRIN2BGRIN2C | |
| SCHEMBL17712350 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139489-A1 | METHODS OF TREATING PAINFUL DIABETIC PERIPHERAL NEUROPATHY | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2021-05-13 | — | — | US | disclosed |
| EP-3458458-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10196401-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10195179-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180093994-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-04-05 | — | — | US | disclosed |
| US-20180092879-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-04-05 | — | — | US | disclosed |
| US-20180093994-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-04-05 | — | — | US | disclosed |
| US-20180092879-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-04-05 | — | — | US | disclosed |
| US-9932347-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932347-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9925169-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925169-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170334922-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2017-11-23 | — | — | US | disclosed |
| US-20170333395-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2017-11-23 | — | — | US | disclosed |
| WO-2017201283-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20170333395-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2017-11-23 | — | — | US | disclosed |
| US-20170334922-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093994-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885CTSL 3797/4885 |
| US-10196401-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885CTSL 3797/4885 |
| US-20170333395-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885CTSL 3751/4885 |
| US-20210139489-A1 | METHODS OF TREATING PAINFUL DIABETIC PERIPHERAL NEUROPATHY | LPXN, PMP22, DPP4 | GRIN2B 689/4885GRIN2C 721/4885CTSL 3776/4885 |
| US-10195179-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885CTSL 3751/4885 |
| US-20170334922-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885CTSL 3797/4885 |
| US-20180092879-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885CTSL 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.